Shots:

• The (ECLIPSE) study evaluating the performance of blood tests vs screening colonoscopy in 20000 avg. risk adults aged 45-84yrs. with CRC across the US. The study evaluates 2 configurations of a multimodal blood-based screening test i.e., cfDNA test & cfDNA test with protein biomarkers
• The results showed an 83% sensitivity for CRC with a specificity of 90% in both individuals without advanced neoplasia & with a negative colonoscopy result while 13% sensitivity in detecting advanced adenomas
• The company is expected to complete its premarket approval submission in the US in Q1’23. The company initiated the (SHIELD LUNG) study in Jan 2022 for individuals undergoing cancer screening across multiple cancer types

Ref: Businesswire | Image: Guardant